Histological parameters | Hepatitic (n=14) | Cholangio-hepatitic (n=6) | Cholangitic (n=4) |
Lobular inflammation | |||
0 | 2 (14%) | 1 (17%) | 0 (0%) |
1 | 3 (21%) | 5 (83%) | 4 (100%) |
2 | 7 (50%) | 0 (0%) | 0 (0%) |
3 | 2 (14%) | 0 (0%) | 0 (0%) |
Lobular necrosis | |||
0 | 2 (14%) | 2 (33%) | 0 (0%) |
1 | 6 (43%) | 4 (67%) | 4 (100%) |
2 | 6 (43%) | 0 (0%) | 0 (0%) |
3 | 0 (0%) | 0 (0%) | 0 (0%) |
Centrilobular injury | |||
0 | 6 (43%) | 5 (83%) | 4 (100%) |
1 | 5 (36%) | 1 (17%) | 0 (0%) |
2 | 2 (14%) | 0 (0%) | 0 (0%) |
3 | 1 (7%) | 0 (0%) | 0 (0%) |
Portal inflammation | |||
0 | 0 (0%) | 0 (0%) | 0 (0%) |
1 | 7 (50%) | 1 (17%) | 1 (25%) |
2 | 4 (29%) | 4 (66%) | 2 (50%) |
3 | 3 (21%) | 1 (17%) | 1 (25%) |
Interface hepatitis | |||
0 | 4 (29%) | 2 (33%) | 0 (0%) |
1 | 6 (43%) | 2 (33%) | 4 (100%) |
2 | 1 (7%) | 2 (33%) | 0 (0%) |
3 | 3 (21%) | 0 (0%) | 0 (0%) |
Specific cell subpopulations Plasma cells | |||
0 | 5 (36%) | 2 (33%) | 1 (25%) |
1 | 8 (57%) | 4 (66%) | 3 (75%) |
2 | 1 (7%) | 0 (0%) | 0 (0%) |
3 | 0 (0%) | 0 (0%) | 0 (0%) |
Eosinophils | |||
0 | 5 (36%) | 1 (17%) | 1 (25%) |
1 | 4 (29%) | 4 (66%) | 2 (50%) |
2 | 5 (36%) | 1 (17%) | 1 (25%) |
Neutrophils | |||
0 | 3 (21%) | 0 (0%) | 0 (0%) |
1 | 9 (64%) | 2 (33%) | 1 (25%) |
2 | 2 (14%) | 4 (67%) | 3 (75%) |
Biliary abnormalities Bile duct injury | |||
0 | 8 (57%) | 0 (0%) | 0 (0%) |
1 | 6 (43%) | 6 (100%) | 4 (100%) |
Ductular reaction | |||
0 | 3 (21%) | 0 (0%) | 0 (0%) |
1 | 8 (57%) | 0 (0%) | 0 (0%) |
2 | 3 (21%) | 5 (83%) | 3 (75%) |
3 | 0 (0%) | 1 (17%) | 1 (25%) |
Biliary metaplasia | |||
0 | 11 (79%) | 1 (17%) | 2 (50%) |
1 | 3 (21%) | 3 (50%) | 0 (0%) |
2 | 0 (0%) | 1 (17%) | 1 (25%) |
3 | 0 (0%) | 1 (17%) | 1 (25%) |
Granulomas | |||
0 | 4 (29%) | 6 (100%) | 1 (25%) |
1 | 7 (50%) | 0 (0%) | 3 (75%) |
2 | 3 (21%) | 0 (0%) | 0 (0%) |
Fibrosis | |||
F0 | 4 (29%) | 0 (0%) | 0 (0%) |
F1 | 9 (64%) | 3 (50%) | 3 (75%) |
F2 | 1 (7%) | 2 (33%) | 0 (0%) |
F2/F3 | 0 (0%) | 1 (17%) | 1 (25%) |
CD4+/CD8+ ratio | 12 | 6 | 4 |
≤1 | 10 (83%) | 4 (66%) | 2 (50%) |
>1 | 2 (17%) | 2 (33%) | 2 (50%) |
One patient had only macrovesicular steatosis at the biopsy and could not be included in either of the immune-related hepatitis, cholangitis or cholangiohepatitis classes. Classification is based on the description of histological features in online supplemental table 4.
irAEs, immune-related adverse events.